President Trump Loves Johnson & Johnson (JNJ), But Insiders Are Selling

Johnson & Johnson (NYSE:JNJ) is 1 of the wellness attraction names that showed up successful President Donald Trump's fiscal disclosures released earlier this year. Now a apical J&J enforcement is heading the different direction.

The Insider Sale

EVP of Global Corporate Affairs Vanessa Broadhurst sold 23,054 shares connected July 20, a transaction worthy adjacent to $5.8 million. That's astir 50% of her stake. The banal is up 27% truthful acold this year. Bulls accidental the insider merchantability reflects immoderate profit-taking and does not constituent to thing alarming. But let's excavation deeper.

The Pipeline Behind the Stock

J&J has spent the past fewer years reshaping itself. The 2023 spin-off of its user wellness portion and the much caller separation of its orthopedics concern into DePuy Synthes were some moves to ore the institution astir higher-growth areas. Management guides to 6% operational income maturation for 2026, with the institution targeting double-digit gross maturation by the extremity of the decade.

That maturation leans connected a heavy pharma pipeline: Tremfya and Icotyde for psoriasis and Crohn's disease, Spravato for treatment-resistant depression, Darzalex, Tecvayli and Talvey for aggregate myeloma, and Rybrevant for lung cancer, positive the OTTAVA soft-tissue surgical robot moving done FDA review. J&J is 1 of lone 2 U.S. companies inactive carrying a AAA recognition rating, and it generates astir $20 cardinal successful escaped currency travel a year, capable to money some the dividend and continued reinvestment.

What the Last Quarter Actually Showed

Recent results backmost up immoderate of that optimism. Revenue roseate 6.6% YoY, with the oncology franchise up 17.3%, led by Darzalex, which grew adjacent to 18% and stayed the company's largest product. Carvykti grew 49.7%.  Tremfya enactment up 72.5% maturation and is taking stock from rival treatments. Management raised its full-year adjusted EPS guidance.

The Not-So-Clean Parts

It's not each upside. Stelara, J&J's older immunology blockbuster, fell YoY arsenic biosimilar contention eats into sales, adjacent though it inactive posted a 12.8% sequential bump. Imbruvica, a humor crab drug, dropped 18.5% connected competitory unit from newer BTK inhibitors. Rybrevant and Lazcluze, J&J's lung crab combination, are increasing acold slower than the $5 billion-plus successful 2030 highest income J&J erstwhile projected for them.

Valuation is different factor. The banal trades astatine a guardant P/E astir 21-22x, astir 10% supra the assemblage median, portion the dividend output sits adjacent 2.2%, debased for what's typically considered an income name. Investors are paying up for the maturation story, not buying it cheap.